Results 171 to 180 of about 18,508 (192)

Dolutegravir/abacavir/dolutegravir/lamivudine

Reactions Weekly, 2018
openaire   +1 more source

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

New England Journal of Medicine, 2021
Barbara Castelnuovo, Agnes N Kiragga, Andrew Kambugu   +2 more
exaly  

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

New England Journal of Medicine, 2021
Anna Turkova, Tim R Cressey, Moherndran Archary   +2 more
exaly  

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Lancet, The, 2013
Carlo Torti, Chloe Orkin, Mark Bloch
exaly  

Dolutegravir

Reactions Weekly
  +5 more sources

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Lancet, The, 2014
Bonaventura Clotet, Judith Feinberg, Andrea Antinori   +2 more
exaly  

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Lancet, The, 2019
Andrea Antinori, Chien-Ching Hung, Jörg Sievers   +2 more
exaly  

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Lancet, The, 2013
Andrey Shuldyakov, Carlos Brites, Jaime F Andrade-Villanueva   +2 more
exaly  

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Lancet, The, 2018
Francesco Castelli, Michael Aboud
exaly  

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Lancet, The, 2017
Paul E Sax, Anton L Pozniak, Andrea Antinori   +2 more
exaly